Open-Label Rollover Study for Continuing Valbenazine Administration for the Treatment of Chorea Associated With Huntington Disease
← catalyst calendarSponsored by Neurocrine Biosciences (industry) · NBIX — their whole pipeline →. With Huntington Study Group.
Phase
Phase 3
Status
Completed
Study type
Interventional
Design
Na · None · Treatment
Enrollment
154actual
Sites
34
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-09-18 | actual | When the study began enrolling |
| Primary completion | 2025-11-05 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-11-05 | actual | The whole study's end, after follow-up |
| First posted | 2020-05-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chorea, Huntington
Intervention
- Drug: Valbenazine — also filed as NBI-98854
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-Emergent Adverse Events (TEAEs)
measured Up to 262 weeks
Permalink · NBIX's whole pipeline · Catalyst calendar · Every registered study · What changed